Viking Therapeutics, Inc.
Every calculator, already run for VKTX
Open the full toolkit →You have the numbers on VKTX. Get the argument.
A written report on which of these readings actually decide the outcome for Viking Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
20 analysts covering VKTXAnalyst Price Target Disagreement for Viking Therapeutics, Inc.
Wall Street's bull case implies +318% from the current price; the bear case implies +27%. A 291% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for VKTX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metab…
VKTX — frequently asked
Is VKTX a buy right now?
Wall Street's consensus rating on Viking Therapeutics, Inc. is Strong Buy across 20 analysts, with a mean price target of $94.82 (+217% vs. the current $29.94). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is VKTX's next earnings date?
Viking Therapeutics, Inc. is next scheduled to report earnings around Oct 28, 2026. A full VKTX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Viking Therapeutics, Inc.?
Analysts covering Viking Therapeutics, Inc. (VKTX) range from a bear-case target of $38.00 to a bull-case high of $125.00, with a mean consensus target of $94.82 across 19 analysts. The spread of $87.00 (291% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Viking Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Viking Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full VKTX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Viking Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.